You are here:

lopinavir/ritonavir (Kaletra)

Advice

Following an abbreviated submission:

lopinavir/ritonavir (Kaletra®) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.

SMC has previously accepted lopinavir/ritonavir for use in children above the age of 2 years.

Drug Details

Drug Name: lopinavir/ritonavir (Kaletra)
SMC Drug ID: 1302/18
Manufacturer: AbbVie Ltd
Indication: in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 12 February 2018

Back